Nature's Sunshine Products (NATR) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Nature's Sunshine Products (NATR) over the past year, gaining 45.5% versus a loss of 51.8%. Over five years, NATR leads with a -40.4% price change compared with -86.4% for WHWK. Whitehawk Therapeutics is the larger company by market cap ($181.2 million vs $176.4 million), about 1.0 times the size, while Nature's Sunshine Products is growing revenue faster (+5.7% vs -72.5%).
Nature's Sunshine Products converts more of its revenue into profit, with a net margin of 4.1% versus -288.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NATR | WHWK |
|---|---|---|
| Share price | $10.18 | $3.07 |
| Market cap | $176.41M | $181.16M |
| 1-day change | +0.10% | -1.60% |
| YTD return | -52.83% | +26.86% |
| 1-year return | -51.84% | +45.50% |
| 5-year return | -40.40% | -86.36% |
| P/E ratio (TTM) | 12.41 | — |
| Forward P/E | 10.77 | — |
| EPS (TTM) | $0.82 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $480.14M | $7.14M |
| Revenue growth (YoY) | +5.67% | -72.50% |
| Net income (latest FY) | $19.52M | $-20.60M |
| Gross margin | 72.42% | 89.36% |
| Operating margin | 5.15% | -1601.12% |
| Net margin | 4.07% | -288.26% |
| 52-week high | $28.14 | $5.50 |
| 52-week low | $9.38 | $2.10 |
| Distance from 52-week high | -63.82% | -44.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +62.08% | +151.14% |
| Average volume | 168.24K | 348.68K |
| Shares outstanding | 17.33M | 59.01M |
| Employees | 806 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed NATR by 97.3 percentage points over the past year.
- Nature's Sunshine Products is more profitable, keeping 4.1 cents of every revenue dollar as net income versus -288.3 cents for Whitehawk Therapeutics.
- Nature's Sunshine Products grew revenue faster in its latest fiscal year (+5.67% vs -72.50%).
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
NATR vs WHWK FAQ
Which is bigger, Nature's Sunshine Products or Whitehawk Therapeutics?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $181.16M compared with $176.41M for Nature's Sunshine Products (NATR).
Which stock has performed better over the past year, NATR or WHWK?
WHWK returned +45.50% over the past 12 months, compared with -51.84% for NATR (price return, excluding dividends). Past performance does not predict future results.
Are Nature's Sunshine Products and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.